Raymond James Comments on TSE:MDP FY2029 Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Analysts at Raymond James issued their FY2029 earnings per share estimates for shares of Medexus Pharmaceuticals in a research report issued on Tuesday, November 19th. Raymond James analyst R. Sarugaser forecasts that the company will earn $0.89 per share for the year. Raymond James has a “Outperform” rating and a $4.00 price target on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share.

MDP has been the subject of a number of other reports. Leede Financial set a C$8.25 price target on Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a report on Monday, September 30th. Stifel Canada upgraded shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research report on Monday, August 12th. Finally, Stifel Nicolaus upped their target price on shares of Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Three equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of C$5.25.

Medexus Pharmaceuticals Stock Performance

Shares of MDP opened at C$2.45 on Thursday. The company has a market cap of C$60.10 million, a price-to-earnings ratio of 42.60 and a beta of 1.96. The stock has a fifty day moving average price of C$2.46 and a two-hundred day moving average price of C$2.19. Medexus Pharmaceuticals has a 52-week low of C$1.44 and a 52-week high of C$3.16.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.